PMID- 22277088
OWN - NLM
STAT- MEDLINE
DCOM- 20120326
LR  - 20220408
IS  - 1532-4303 (Electronic)
IS  - 0277-0903 (Linking)
VI  - 49
IP  - 2
DP  - 2012 Mar
TI  - Clinically significant variability of serum IgE concentrations in patients with 
      severe asthma.
PG  - 115-20
LID - 10.3109/02770903.2011.649871 [doi]
AB  - OBJECTIVE: To determine the magnitude of immunoglobulin E (IgE) variability in a 
      cohort of patients with severe asthma considered for omalizumab therapy. METHODS: 
      Retrospective chart review identified 65 patients with two or more IgE 
      determinations out of the 124 patients referred to the Cleveland Clinic 
      Respiratory Institute for treatment with omalizumab from 2003 to 2011. Patients 
      with conditions known to affect IgE concentrations were excluded. Demographic 
      data, pulmonary function testing, medications, smoking status, and atopy were 
      recorded. The range of variability and percent variability in relation to 
      baseline serum IgE were calculated. RESULTS: The median difference of serum IgE 
      between the minimal and maximal values was 94.9 IU/ml (IQR 26.3-324.1 IU/ml). 
      Percent variability from minimum value had a median of 75.5% (IQR 23.3-152.6%). 
      There was no correlation between age, body mass index, lung function, and IgE 
      variability. Greater variability was associated with female gender (p = .06). 
      There was no association with peripheral eosinophilia, systemic corticosteroid 
      use, and leukotriene modifier use at presentation. The observed variability would 
      have affected omalizumab dosing in 20 out of 42 patients. Six patients who may 
      have qualified at different time points would not have been deemed candidates 
      based on an IgE concentration <30 IU/ml or >700 IU/ml. CONCLUSION: Serum IgE 
      concentration may have clinically significant variability over time, affecting 
      candidacy and dosing of omalizumab. Our findings imply that repeating serum IgE 
      determinations merits consideration for patients whose initial concentrations are 
      <30 or >700 IU/ml. Prospective studies are warranted to delineate the factors 
      that contribute to IgE variability.
FAU - Mummadi, Srinivas R
AU  - Mummadi SR
AD  - Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
FAU - Hatipoglu, Umur Sevket
AU  - Hatipoglu US
FAU - Gupta, Manjula
AU  - Gupta M
FAU - Bossard, Mary Kay
AU  - Bossard MK
FAU - Xu, Meng
AU  - Xu M
FAU - Lang, David
AU  - Lang D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120125
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (anti-IgE antibodies)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Anti-Idiotypic/therapeutic use
MH  - Asthma/*immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
EDAT- 2012/01/27 06:00
MHDA- 2012/03/27 06:00
CRDT- 2012/01/27 06:00
PHST- 2012/01/27 06:00 [entrez]
PHST- 2012/01/27 06:00 [pubmed]
PHST- 2012/03/27 06:00 [medline]
AID - 10.3109/02770903.2011.649871 [doi]
PST - ppublish
SO  - J Asthma. 2012 Mar;49(2):115-20. doi: 10.3109/02770903.2011.649871. Epub 2012 Jan 
      25.